Microbiotica

Company history

Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Sanger Institute. The company retains a close association with the Sanger Institute and its founders and is based at the BioData Innovation Centre here on Campus.

Platform

The Microbiotica platform is based on world leading tools developed at the Wellcome Sanger Institute that unblock the barriers to discovery. These are founded on a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling precise association of bacteria to function for the first time. They also include the leading microbiota culture collection and reference genome database which provide resources for precise metagenomic analysis and functional studies and humanised in vitro and in vivo models of disease. Using these tools Microbiotica starts programs with deep analysis of samples from clinical trials and progresses medicines and biomarkers through lab testing back into the clinic.

Pipeline

Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota. These programs start with deep metagenomic and culture-based analysis of patient samples linked to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models. The company’s C. difficile defined live bacterial therapeutic asset will be used to validate our manufacturing and delivery technologies.

Contact us

info@microbiotica.com

Who is here?

The Campus is home to a range of partner companies, facilities, and cross-cutting activities.

Learn more